Axon Enterprise (NASDAQ:AXON – Get Free Report) had its price objective lifted by investment analysts at The Goldman Sachs Group from $500.00 to $700.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price target suggests a potential upside of 9.80% from the stock’s current price.
Several other brokerages have also recently weighed in on AXON. JMP Securities raised their price target on shares of Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research report on Thursday, October 31st. Northland Securities increased their price objective on Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. TD Cowen initiated coverage on Axon Enterprise in a research report on Wednesday, January 8th. They set a “buy” rating and a $700.00 target price on the stock. Morgan Stanley raised Axon Enterprise from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $500.00 to $700.00 in a research report on Tuesday, December 3rd. Finally, Needham & Company LLC increased their target price on shares of Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $524.85.
Read Our Latest Research Report on Axon Enterprise
Axon Enterprise Price Performance
Insiders Place Their Bets
In other news, insider Jeffrey C. Kunins sold 21,834 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $593.88, for a total transaction of $12,966,775.92. Following the completion of the transaction, the insider now owns 154,394 shares of the company’s stock, valued at approximately $91,691,508.72. The trade was a 12.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total transaction of $271,831.50. Following the completion of the sale, the director now directly owns 6,929 shares in the company, valued at $4,185,601.03. This represents a 6.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,545 shares of company stock worth $30,721,337 in the last three months. 6.10% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Axon Enterprise
A number of hedge funds and other institutional investors have recently bought and sold shares of AXON. Quent Capital LLC grew its position in Axon Enterprise by 1,875.0% in the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 75 shares in the last quarter. Prestige Wealth Management Group LLC boosted its holdings in shares of Axon Enterprise by 115.8% in the 3rd quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 44 shares in the last quarter. New Wave Wealth Advisors LLC bought a new position in shares of Axon Enterprise during the 4th quarter valued at about $40,000. Brooklyn Investment Group purchased a new position in shares of Axon Enterprise during the 3rd quarter valued at about $41,000. Finally, Y.D. More Investments Ltd bought a new stake in Axon Enterprise in the 4th quarter worth approximately $45,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.
About Axon Enterprise
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Featured Stories
- Five stocks we like better than Axon Enterprise
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- How Technical Indicators Can Help You Find Oversold Stocks
- What Does the Future Hold for Eli Lilly?
- Profitably Trade Stocks at 52-Week Highs
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.